Success Metrics

Clinical Success Rate
57.1%

Based on 4 completed trials

Completion Rate
57%(4/7)
Active Trials
0(0%)
Results Posted
125%(5 trials)
Terminated
3(43%)

Phase Distribution

Ph phase_3
3
43%
Ph phase_1
3
43%
Ph phase_2
1
14%

Phase Distribution

3

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
3(42.9%)
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
3(42.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(4)
Terminated(3)

Detailed Status

Completed4
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
57.1%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (42.9%)
Phase 21 (14.3%)
Phase 33 (42.9%)

Trials by Status

completed457%
terminated343%

Recent Activity

0 active trials
Showing 5 of 7
terminatedphase_3

Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

NCT05026177
terminatedphase_2

Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease

NCT05352763
completedphase_3

Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

NCT04994483
terminatedphase_3

Open-label Extension for Phase 3 Clinical Trials of Simufilam

NCT05575076
completedphase_1

Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects

NCT06195319
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT05026177Phase 3

Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Terminated
NCT05352763Phase 2

Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease

Terminated
NCT04994483Phase 3

Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

Completed
NCT05575076Phase 3

Open-label Extension for Phase 3 Clinical Trials of Simufilam

Terminated
NCT06195319Phase 1

Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects

Completed
NCT06390410Phase 1

A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function

Completed
NCT04932655Phase 1

Food Effect and Bioequivalence Study of Simufilam Tablets in Healthy Volunteers

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7